Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
910.28B
Market cap910.28B
Price-Earnings ratio
33.64
Price-Earnings ratio33.64
Dividend yield
0.67%
Dividend yield0.67%
Average volume
3.59M
Average volume3.59M
High today
$984.45
High today$984.45
Low today
$938.00
Low today$938.00
Open price
$949.16
Open price$949.16
Volume
3.02M
Volume3.02M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

Eli Lilly(LLY) stock is priced at $963.44, giving the company a market capitalization of 910.28B. It carries a P/E multiple of 33.64 and pays a dividend yield of 66.7%.

On 2026-05-01, Eli Lilly(LLY) stock traded between a low of $938.00 and a high of $984.45. Shares are currently priced at $963.44, which is +2.7% above the low and -2.1% below the high.

The Eli Lilly(LLY)'s current trading volume is 3.02M, compared to an average daily volume of 3.59M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

LLY News

Investor's Business Daily 2h
There's Another Twist In The Obesity Pills Showdown — And This One Actually Helps Lilly

Technology There's Another Twist In The Obesity Pills Showdown — And This One Actually Helps Lilly Licensing The prescription data collected for Eli Lilly's (LL...

There's Another Twist In The Obesity Pills Showdown — And This One Actually Helps Lilly
TipRanks 3h
Eli Lilly price target raised to $1,344 from $1,327 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,344 from $1,327 and keeps an Overweight rating on the shares. The firm sees Eli Lilly’s Q...

Benzinga 6h
Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules

The drugmaker reported adjusted earnings of $8.55 per share, topping analyst estimates of $6.66, while revenue rose to $19.79 billion versus expectations of $17...

Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
12.1%
Sell
3%

More LLY News

Benzinga 13h
Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Still Looks Compelling'

Fueling The ‘Love Affair’ Eli Lilly's revenue skyrocketed 56% year-over-year to $19.8 billion during its first-quarter 2026, driven primarily by the astronomica...

Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Still Looks Compelling'
Seeking Alpha 24h
Lilly projects 2026 revenue of $82B-$85B and non-GAAP EPS of $35.50-$37 as Foundayo launch begins

Earnings Call Insights Lilly projects 2026 revenue of $82B-$85B and non-GAAP EPS of $35.50-$37 as Foundayo launch begins Apr 30, 2026, 3:12 PM ET Eli Lilly and...

Lilly projects 2026 revenue of $82B-$85B and non-GAAP EPS of $35.50-$37 as Foundayo launch begins
Sherwood News 1d
Eli Lilly quells fears that its GLP-1 pill debut is off to a rocky start

Early prescription data for Foundayo showed the pill was having a lackluster rollout compared to its competitor. Going into its Thursday morning earnings repor...

Eli Lilly quells fears that its GLP-1 pill debut is off to a rocky start
Benzinga 1d
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand

Earnings Overview Shows Strong Growth Eli Lilly reported first-quarter adjusted earnings of $8.55 per share, beating the consensus of $6.66. The company’s sales...

Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand
TipRanks 1d
Eli Lilly, Novo Nordisk Stocks Jump as FDA Moves Against Bulk Production of Obesity Drug Ingredients

Shares in drugmakers Eli Lilly (LLY) and Novo Nordisk (NVO) climbed on Thursday morning after the U.S. health watchdog proposed not to allow outsourcing facilit...

Nasdaq 1d
Why Eli Lilly Stock Just Popped

Key Points Eli Lilly beat on both top and bottom lines this morning. The company's GLP-1 business is doing fine despite pricing pressure. Now, Lilly is focus...

Why Eli Lilly Stock Just Popped
CNBC 1d
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. The ⁠Food and Drug ⁠Administration on Thursday proposed ​ex...

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.